trending Market Intelligence /marketintelligence/en/news-insights/trending/YZsR9u0CiwIq-qomxG5q6w2 content esgSubNav
In This List

Sarepta Therapeutics' Q2 net loss widens YOY

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Sarepta Therapeutics' Q2 net loss widens YOY

Sarepta Therapeutics Inc.'s non-GAAP net loss came to 83 cents per share in the second quarter, compared with the S&P Global Market Intelligence consensus normalized EPS estimate loss of 77 cents per share.

The Cambridge, Mass.-based company's loss per share was 43 cents in the year-ago period. Non-GAAP net loss widened by 118.6% to $61.2 million from $28 million in the prior-year period.

GAAP net loss increased by 152.9% from the prior-year period to $276.4 million, or $3.74 per share, from $109.3 million, or $1.67 per share.

The company noted that it recorded acquired in-process research and development expense of about $173.2 million during the second quarter related to its acquisition of gene therapy developer Myonexus Therapeutics Inc.

Sarepta said its revenues in the quarter climbed 28.8% year over year to $94.7 million from $73.5 million. The company develops RNA-based therapeutics for treating rare neuromuscular diseases.